Narazaciclib | ON 123300 | CDK4/ARK5 Inhibitor | AmBeed-信号通路专用抑制剂

Narazaciclib {[allProObj[0].p_purity_real_show]}

货号：A414519 同义名： ON 123300; ON123300

Narazaciclib是一种强效的多靶点激酶抑制剂，可抑制 CDK4、Ark5、PDGFRβ、FGFR1、RET 和 Fyn，IC50 分别为 3.9 nM、5 nM、26 nM、26 nM、9.2 nM 和 11 nM。

Narazaciclib 化学结构
CAS号：1357470-29-1

Narazaciclib 3D分子结构
CAS号：1357470-29-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

CDK 亚型比较

产品名称	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 HCl	++++ Cdc7, IC50: 3.4 nM													99%+
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								99%+
RO-3306		+++ CDK1, Ki: 20 nM											SGK,ERK	98%
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								99%+
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								99%+
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	98%
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinE, IC50: 35 nM CDK2/CyclinA, IC50: 70 nM		+ CDK4/CyclinD1, IC50: 850 nM								99%+
SCH900776				++ CDK2, IC50: 0.16 μM										99%+
AUZ 454				++++ CDK2(C118L), Kd: 18.6 nM CDK2(A144C), Kd: 9.7 nM										99%+
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	99%
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinE, IC50: 3 nM CDK2/CyclinA, IC50: 4 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						99%+
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			98+%
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinE, IC50: 8 nM CDK2/CyclinA, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			99%+
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinE, IC50: 363 nM CDK2/CyclinA, IC50: 45 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					99%+
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinE, IC50: 7.5μM CDK2/CyclinA, IC50: 0.68μM			+ CDK5/p35, IC50: 0.85μM							98%
SNS-032				+++ CDK2/CyclinE, IC50: 48 nM CDK2/CyclinA, IC50: 38 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			99%+
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			99%+
PHA-767491 HCl	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	99%
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinE, IC50: 0.7 μM CDK2/CyclinA, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							99%+
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	99%+
Palbociclib						++++ CDK4/CyclinD3, IC50: 9 nM CDK4/CyclinD1, IC50: 11 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						99%
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						98%
Palbociclib isethionate						++++ CDK4/CyclinD3, IC50: 9 nM CDK4/CyclinD1, IC50: 11 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%+
BS-181 HCl									+++ CDK7, IC50: 21 nM					99%+
(E/Z)-THZ1 2HCl									++++ CDK7, IC50: 3.2 nM					99%+
LDC4297									++++ CDK7, IC50: 0.13 nM					99%+
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				99%
MSC2530818										++++ CDK8, IC50: 2.6 nM				99%+
Wogonin											✔			99%+
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinE, IC50: 2.54 μM CDK2/CyclinA, IC50: 224 nM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			98%
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			98%
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			99%+
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			99%+
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			99%+
ML167												++ Dyrk1B , IC50: 1648 nM CLK4, IC50: 136 nM		99%+
(E/Z)-TG003												+++ mCLK1, IC50: 200 nM mCLK4, IC50: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Narazaciclib 生物活性

靶点

FGFR1

FGFR1, IC50:26 nM
CDK4

CDK4/CyclinD1, IC50:3.87 nM
CDK6

CDK6/CyclinD1, IC50:9.82 nM

描述

The cyclin-dependent kinases (CDKs) have a central role in coordinating the eukaryotic cell division cycle, and also serve to integrate diverse growth-regulatory signals^[5]. ON123300 is an effective multi-target kinase inhibitor against CDK4 and ARK5, two kinases intimately associated with growth, survival and metastasis of human tumor cells with IC₅₀s of 3.9 nM, 5 nM, respectively. Z138C cells treated with ON123300 for 24 hours accumulated in the G₁ phase at lower concentrations (0.1–1.0 µM), at higher concentrations of this compound, a large proportion of the cells progressed through the S and G₂/M phases of the cell cycle and eventually accumulated in the sub-G₁ phase, suggesting an induction of apoptosis. Granta 519 and Z138C cells were treated with increasing concentrations of ON123300 for 24 hours. ON123300 repressed the phosphorylation of pRb and p130 in a dose-dependent manner suggesting that ON123300 inactivated the Rb (Retinoblastoma family of proteins) pathway due to the inhibition of CDK4 in the two MCL (mantle cell lymphoma) cell lines. Mice with tumor xenografts were randomly assigned into 2 treatment groups and treated daily with either water (vehicle) or ON123300 (100mg/kg) on a daily basis. Treatment with ON123300 significantly inhibited (p<0.05) tumor growth over a 2-week period, suggesting that this compound is a potent inhibitor of MCL proliferation in vivo^[6].

Narazaciclib 细胞实验

Cell Line Ba/F3-FLT3-ITD cells M2-Macrophages Ba/F3-RBM6-CSF1R cells Ba/F3-CSF1R cells GBM39 cells U87 cells U87 glioma cells MEM2 (ibrutinib-resistant MCL) MEM1 (ibrutinib-sensitive MCL) Z138C Granta 519 multiple myeloma cell lines EJM multiple myeloma cell lines MM1.S multiple myeloma cell lines NCI-H929 multiple myeloma cell lines MM.1R Ba/F3-FLT3-ITD cells M2 primary macrophages Ba/F3-RBM6-CSF1R cells Ba/F3-CSF1R cells	Concentration	Treated Time	Description	References
Ba/F3-FLT3-ITD cells	95.32 nM		Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-FLT3-ITD cells, showing potent inhibition.	Sci Rep. 2024 Apr 19;14(1):9032.
M2-Macrophages	72.5 nM		Tested the inhibitory effect of Narazaciclib on the proliferation of M2-Macrophages, showing potent inhibition.	Sci Rep. 2024 Apr 19;14(1):9032.
Ba/F3-RBM6-CSF1R cells	36.94 nM		Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-RBM6-CSF1R cells, showing potent inhibition.	Sci Rep. 2024 Apr 19;14(1):9032.
Ba/F3-CSF1R cells	3.54 nM		Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-CSF1R cells, showing potent inhibition.	Sci Rep. 2024 Apr 19;14(1):9032.
GBM39 cells	4 μM		Evaluate the effect of ON123300 on phosphorylation of Akt and Erk in GBM39 cells, showing 55% inhibition of Akt phosphorylation and 174% activation of Erk phosphorylation	Mol Cancer Ther. 2014 May;13(5):1105-16.
U87 cells	6.3 μM	1 h	Evaluate the inhibitory effect of ON123300 on phosphorylation of Akt and its downstream signaling molecules, showing decreased phosphorylation levels of Akt, P70S6K, rpS6, and Rb S780, while increased phosphorylation of Erk	Mol Cancer Ther. 2014 May;13(5):1105-16.
U87 glioma cells	3.4 ± 0.1 μM(IC50)	72 h	Evaluate the inhibitory effect of ON123300 on U87 glioma cell proliferation, showing an IC50 of 3.4 ± 0.1 μM	Mol Cancer Ther. 2014 May;13(5):1105-16.
MEM2 (ibrutinib-resistant MCL)	500nM–5µM	24 h	ON123300 induced apoptosis in both ibrutinib-sensitive and resistant MCL cells	Leukemia. 2016 Jan;30(1):86-93.
MEM1 (ibrutinib-sensitive MCL)	500nM–5µM	24 h	ON123300 induced apoptosis in both ibrutinib-sensitive and resistant MCL cells	Leukemia. 2016 Jan;30(1):86-93.
Z138C	0.1–1.0µM(IC50)	24 h	ON123300 induced G1 phase cell cycle arrest at lower concentrations and apoptosis at higher concentrations	Leukemia. 2016 Jan;30(1):86-93.
Granta 519	0.1–1.0µM(IC50)	24 h	ON123300 induced G1 phase cell cycle arrest at lower concentrations and apoptosis at higher concentrations	Leukemia. 2016 Jan;30(1):86-93.
multiple myeloma cell lines EJM	50 nM	48 h	To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration	Cancer Res. 2016 Mar 1;76(5):1225-36.
multiple myeloma cell lines MM1.S	50 nM	48 h	To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration	Cancer Res. 2016 Mar 1;76(5):1225-36.
multiple myeloma cell lines NCI-H929	50 nM	48 h	To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration	Cancer Res. 2016 Mar 1;76(5):1225-36.
multiple myeloma cell lines MM.1R	50 nM	48 h	To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration	Cancer Res. 2016 Mar 1;76(5):1225-36.
Ba/F3-FLT3-ITD cells	95.32 nM(IC50)		To test the inhibitory effect of ON123300 on FLT3-ITD-driven cell proliferation	Sci Rep. 2024 Apr 19;14(1):9032.
M2 primary macrophages	72.5 nM(IC50)	7 days	To test the inhibitory effect of ON123300 on M2 macrophage proliferation	Sci Rep. 2024 Apr 19;14(1):9032.
Ba/F3-RBM6-CSF1R cells	36.94 nM(IC50)		To test the inhibitory effect of ON123300 on RBM6-CSF1R fusion protein-driven cell proliferation	Sci Rep. 2024 Apr 19;14(1):9032.
Ba/F3-CSF1R cells	3.54 nM(IC50)		To test the inhibitory effect of ON123300 on CSF1R-driven cell proliferation	Sci Rep. 2024 Apr 19;14(1):9032.

Cell Line

Concentration

Treated Time

Description

References

Ba/F3-FLT3-ITD cells

95.32 nM

Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-FLT3-ITD cells, showing potent inhibition.

Sci Rep. 2024 Apr 19;14(1):9032.

M2-Macrophages

72.5 nM

Tested the inhibitory effect of Narazaciclib on the proliferation of M2-Macrophages, showing potent inhibition.

Sci Rep. 2024 Apr 19;14(1):9032.

Ba/F3-RBM6-CSF1R cells

36.94 nM

Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-RBM6-CSF1R cells, showing potent inhibition.

Sci Rep. 2024 Apr 19;14(1):9032.

Ba/F3-CSF1R cells

3.54 nM

Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-CSF1R cells, showing potent inhibition.

Sci Rep. 2024 Apr 19;14(1):9032.

GBM39 cells

4 μM

Evaluate the effect of ON123300 on phosphorylation of Akt and Erk in GBM39 cells, showing 55% inhibition of Akt phosphorylation and 174% activation of Erk phosphorylation

Mol Cancer Ther. 2014 May;13(5):1105-16.

U87 cells

6.3 μM

1 h

Evaluate the inhibitory effect of ON123300 on phosphorylation of Akt and its downstream signaling molecules, showing decreased phosphorylation levels of Akt, P70S6K, rpS6, and Rb S780, while increased phosphorylation of Erk

Mol Cancer Ther. 2014 May;13(5):1105-16.

U87 glioma cells

3.4 ± 0.1 μM(IC50)

72 h

Evaluate the inhibitory effect of ON123300 on U87 glioma cell proliferation, showing an IC50 of 3.4 ± 0.1 μM

Mol Cancer Ther. 2014 May;13(5):1105-16.

MEM2 (ibrutinib-resistant MCL)

500nM–5µM

24 h

ON123300 induced apoptosis in both ibrutinib-sensitive and resistant MCL cells

Leukemia. 2016 Jan;30(1):86-93.

MEM1 (ibrutinib-sensitive MCL)

500nM–5µM

24 h

ON123300 induced apoptosis in both ibrutinib-sensitive and resistant MCL cells

Leukemia. 2016 Jan;30(1):86-93.

Z138C

0.1–1.0µM(IC50)

24 h

ON123300 induced G1 phase cell cycle arrest at lower concentrations and apoptosis at higher concentrations

Leukemia. 2016 Jan;30(1):86-93.

Granta 519

0.1–1.0µM(IC50)

24 h

ON123300 induced G1 phase cell cycle arrest at lower concentrations and apoptosis at higher concentrations

Leukemia. 2016 Jan;30(1):86-93.

multiple myeloma cell lines EJM

50 nM

48 h

To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration

Cancer Res. 2016 Mar 1;76(5):1225-36.

multiple myeloma cell lines MM1.S

50 nM

48 h

To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration

Cancer Res. 2016 Mar 1;76(5):1225-36.

multiple myeloma cell lines NCI-H929

50 nM

48 h

To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration

Cancer Res. 2016 Mar 1;76(5):1225-36.

multiple myeloma cell lines MM.1R

50 nM

48 h

To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nmol/L concentration

Cancer Res. 2016 Mar 1;76(5):1225-36.

Ba/F3-FLT3-ITD cells

95.32 nM(IC50)

To test the inhibitory effect of ON123300 on FLT3-ITD-driven cell proliferation

Sci Rep. 2024 Apr 19;14(1):9032.

M2 primary macrophages

72.5 nM(IC50)

7 days

To test the inhibitory effect of ON123300 on M2 macrophage proliferation

Sci Rep. 2024 Apr 19;14(1):9032.

Ba/F3-RBM6-CSF1R cells

36.94 nM(IC50)

To test the inhibitory effect of ON123300 on RBM6-CSF1R fusion protein-driven cell proliferation

Sci Rep. 2024 Apr 19;14(1):9032.

Ba/F3-CSF1R cells

3.54 nM(IC50)

To test the inhibitory effect of ON123300 on CSF1R-driven cell proliferation

Sci Rep. 2024 Apr 19;14(1):9032.

Narazaciclib 动物实验

Species Mice NIH Swiss nude mice CD-1 mice NSG mice NOD/scid mice	Animal Model MV4-11 subcutaneous tumor model U87 glioma model Z138C cell xenograft model Multiple myeloma xenograft model MV4-11 subcutaneous tumor model	Administration	Dosage	Frequency	Description	References
Mice	MV4-11 subcutaneous tumor model	Intraperitoneal injection	100 mg/kg	Twice per week for 3 weeks	Tested the inhibitory effect of Narazaciclib on MV4-11 subcutaneous tumor growth, showing significant inhibition.	Sci Rep. 2024 Apr 19;14(1):9032.
NIH Swiss nude mice	U87 glioma model	Intravenous injection	5 mg/kg and 25 mg/kg	Single dose	Evaluate the pharmacokinetic and pharmacodynamic properties of ON123300 in the U87 glioma model, showing high distribution of ON123300 in brain and brain tumor with a brain partition coefficient of at least 2.5. Single agent ON123300 caused dose-dependent suppression of Akt phosphorylation and activation of Erk, while addition of GFN significantly enhanced p-Akt inhibition and prevented Erk activation	Mol Cancer Ther. 2014 May;13(5):1105-16.
CD-1 mice	Z138C cell xenograft model	Intraperitoneal injection	100mg/kg	Daily or every alternate day for 14 days	ON123300 significantly inhibited MCL tumor growth without obvious toxicity	Leukemia. 2016 Jan;30(1):86-93.
NSG mice	Multiple myeloma xenograft model	Intraperitoneal injection	100 mg/kg	Administered every alternate day until tumor diameter exceeded 1 cm or body weight loss exceeded 10%	To evaluate the in vivo antitumor effect of ON123300 on multiple myeloma, results showed that ON123300 significantly inhibited tumor growth	Cancer Res. 2016 Mar 1;76(5):1225-36.
NOD/scid mice	MV4-11 subcutaneous tumor model	Intraperitoneal injection	100 mg/kg	Twice per week for 3 weeks	To test the inhibitory effect of ON123300 on FLT3-ITD-driven AML tumor growth	Sci Rep. 2024 Apr 19;14(1):9032.

Species

Mice NIH Swiss nude mice CD-1 mice NSG mice NOD/scid mice

Animal Model

MV4-11 subcutaneous tumor model U87 glioma model Z138C cell xenograft model Multiple myeloma xenograft model MV4-11 subcutaneous tumor model

Administration

Dosage

Frequency

Description

References

Mice

MV4-11 subcutaneous tumor model

Intraperitoneal injection

100 mg/kg

Twice per week for 3 weeks

Tested the inhibitory effect of Narazaciclib on MV4-11 subcutaneous tumor growth, showing significant inhibition.

Sci Rep. 2024 Apr 19;14(1):9032.

NIH Swiss nude mice

U87 glioma model

Intravenous injection

5 mg/kg and 25 mg/kg

Single dose

Evaluate the pharmacokinetic and pharmacodynamic properties of ON123300 in the U87 glioma model, showing high distribution of ON123300 in brain and brain tumor with a brain partition coefficient of at least 2.5. Single agent ON123300 caused dose-dependent suppression of Akt phosphorylation and activation of Erk, while addition of GFN significantly enhanced p-Akt inhibition and prevented Erk activation

Mol Cancer Ther. 2014 May;13(5):1105-16.

CD-1 mice

Z138C cell xenograft model

Intraperitoneal injection

100mg/kg

Daily or every alternate day for 14 days

ON123300 significantly inhibited MCL tumor growth without obvious toxicity

Leukemia. 2016 Jan;30(1):86-93.

NSG mice

Multiple myeloma xenograft model

Intraperitoneal injection

100 mg/kg

Administered every alternate day until tumor diameter exceeded 1 cm or body weight loss exceeded 10%

To evaluate the in vivo antitumor effect of ON123300 on multiple myeloma, results showed that ON123300 significantly inhibited tumor growth

Cancer Res. 2016 Mar 1;76(5):1225-36.

NOD/scid mice

MV4-11 subcutaneous tumor model

Intraperitoneal injection

100 mg/kg

Twice per week for 3 weeks

To test the inhibitory effect of ON123300 on FLT3-ITD-driven AML tumor growth

Sci Rep. 2024 Apr 19;14(1):9032.

Narazaciclib 动物研究

Dose

Rat: 5 mg/kg, 10 mg/kg^[3] (i.v.); 25 mg/kg, 200 mg/kg^[3] (p.o.) Mice: 125 mg/kg^[4] (p.o.)

Administration

i.v., p.o.

Pharmacokinetics

Animal	Rats^[3]
Dose	10 mg/kg
Administration	i.v.
V	4.72 ± 0.99 L/kg (male) 2.85 ± 0.17 L/kg (female)
T_1/2	0.71 ± 0.10 h (male) 0.87 ± 0.12 h (female)
CL	75.90 ± 4.66 ml/min/kg (male) 38.44 ± 4.60 ml/min/kg (female)
AUC_0→∞	2200 ± 136 ng·h/ml (male) 4399 ± 542 ng·h/ml (female)

Narazaciclib 参考文献

Narazaciclib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.64mL

2.33mL

1.16mL

23.28mL

4.66mL

2.33mL

Narazaciclib 技术信息

CAS号	1357470-29-1
分子式	C₂₄H₂₇N₇O
分子量	429.52
SMILES Code	N#CC1=CC2=CN=C(NC3=CC=C(N4CCN(C)CC4)C=C3)N=C2N(C5CCCC5)C1=O
MDL No.	MFCD28411414

别名	ON 123300; ON123300
运输	蓝冰
InChI Key	VADOZMZXXRBXNY-UHFFFAOYSA-N
Pubchem ID	56649281

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C

溶解方案

细胞实验：

DMSO: 16 mg/mL(37.25 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

Narazaciclib {[allProObj[0].p_purity_real_show]}

Narazaciclib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Narazaciclib 质控信息

Narazaciclib 生物活性

Narazaciclib 细胞实验

Narazaciclib 动物实验

Narazaciclib 动物研究

Narazaciclib 参考文献

Narazaciclib 实验方案

Narazaciclib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

FGFR1	FGFR1, IC50:26 nM
CDK4	CDK4/CyclinD1, IC50:3.87 nM
CDK6	CDK6/CyclinD1, IC50:9.82 nM

Narazaciclib {[allProObj[0].p_purity_real_show]}

Narazaciclib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Narazaciclib 质控信息

Narazaciclib 生物活性

Narazaciclib 细胞实验

Narazaciclib 动物实验

Narazaciclib 动物研究

Narazaciclib 参考文献

Narazaciclib 实验方案

Narazaciclib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Narazaciclib 纯度/质量文件产品仅供科研